Imaging of prostate cancer (Pca) presents many challenges as imaging tools aim to improve cancer detection, assessment in biochemical relapse, and disease progression in advanced metastatic stages. Current imaging modalities have strengths but also weaknesses, such as the lack of ability to diagnose micrometastases, to differentiate significant from nonsignificant cancer, and to diagnose advanced disease at low prostate-specific antigen values. Some of the modalities appear promising in increasing the sensitivity and specificity rate, particularly in recurrent and advanced disease (e.g., prostate-specific membrane antigen–positron emission tomography). Others can prove valuable in delivering focal therapy for Pca. Finally, the combination of two modalities could provide improved results in the diagnosis of Pca. Despite promising results, most guidelines still recommend traditional imaging modalities, such as 99m Tc bone scintigraphy and computed tomography, for the estimation of metastatic spread in bones and lymph nodes, and the routine use of the novel techniques is not considered. Prospective studies clarify the value of the modalities and determine their role in clinical practice.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.